Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,384,628 shares of MRUS stock, worth $216 Million. This represents 4.09% of its overall portfolio holdings.
Number of Shares
3,384,628
Previous 3,173,928
6.64%
Holding current value
$216 Million
Previous $134 Million
33.27%
% of portfolio
4.09%
Previous 3.38%
Shares
13 transactions
Others Institutions Holding MRUS
# of Institutions
217Shares Held
65.3MCall Options Held
311KPut Options Held
556K-
Paradigm Biocapital Advisors LP New York, NY4.28MShares$273 Million10.51% of portfolio
-
Rtw Investments, LP New York, NY4MShares$255 Million3.23% of portfolio
-
Wellington Management Group LLP Boston, MA3.73MShares$238 Million0.04% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$225 Million17.29% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.16MShares$201 Million3.03% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.93B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...